Posted by Michael Wonder on 10 Jun 2025
X4 Pharmaceuticals granted fast track designation for mavorixafor for the treatment of chronic neutropenia by US FDA
10 June 2025 - X4 Pharmaceuticals today announced that the US FDA has granted fast track designation to mavorixafor, an oral CXCR4 antagonist, for the treatment of chronic neutropenia.
The company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in certain primary chronic neutropenia conditions.
